These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 34530487)
1. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Mintoff D; Benhadou F; Pace NP; Frew JW Int J Dermatol; 2022 Oct; 61(10):1175-1186. PubMed ID: 34530487 [TBL] [Abstract][Full Text] [Related]
2. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. Gold DA; Reeder VJ; Mahan MG; Hamzavi IH J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875 [TBL] [Abstract][Full Text] [Related]
3. Association of metabolic syndrome and hidradenitis suppurativa. Miller IM; Ellervik C; Vinding GR; Zarchi K; Ibler KS; Knudsen KM; Jemec GB JAMA Dermatol; 2014 Dec; 150(12):1273-80. PubMed ID: 25229996 [TBL] [Abstract][Full Text] [Related]
4. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Garg A; Malviya N; Strunk A; Wright S; Alavi A; Alhusayen R; Alikhan A; Daveluy SD; Delorme I; Goldfarb N; Gulliver W; Hamzavi I; Jaleel T; Kimball AB; Kirby JS; Kirchhof MG; Lester J; Lev-Tov H; Lowes MA; Micheletti R; Orenstein LA; Piguet V; Sayed C; Tan J; Naik HB J Am Acad Dermatol; 2022 May; 86(5):1092-1101. PubMed ID: 33493574 [TBL] [Abstract][Full Text] [Related]
5. Association Between Hidradenitis Suppurativa and Metabolic Syndrome: A Systematic Review and Meta-analysis. Rodríguez-Zuñiga MJM; García-Perdomo HA; Ortega-Loayza AG Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):279-288. PubMed ID: 30846164 [TBL] [Abstract][Full Text] [Related]
6. What is hidradenitis suppurativa? Lee EY; Alhusayen R; Lansang P; Shear N; Yeung J Can Fam Physician; 2017 Feb; 63(2):114-120. PubMed ID: 28209676 [TBL] [Abstract][Full Text] [Related]
8. Hidradenitis Suppurativa: A Frequently Missed Diagnosis, Part 1: A Review of Pathogenesis, Associations, and Clinical Features. Wang SC; Wang SC; Sibbald RG; Alhusayen R; Bashash M; Alavi A Adv Skin Wound Care; 2015 Jul; 28(7):325-32; quiz 333-4. PubMed ID: 26080019 [TBL] [Abstract][Full Text] [Related]
9. Epidemiologic and clinical features of hidradenitis suppurativa. Parulkar I; Haleem H; Paek SY Semin Cutan Med Surg; 2017 Jun; 36(2):42-46. PubMed ID: 28538742 [TBL] [Abstract][Full Text] [Related]
11. Which hidradenitis suppurativa comorbidities should I take into account? Tzellos T; Zouboulis CC Exp Dermatol; 2022 Sep; 31 Suppl 1():29-32. PubMed ID: 35737874 [TBL] [Abstract][Full Text] [Related]
12. Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa/Acne Inversa. Hunger RE; Laffitte E; Läuchli S; Mainetti C; Mühlstädt M; Schiller P; Lapointe AK; Meschberger P; Navarini AA Dermatology; 2017; 233(2-3):113-119. PubMed ID: 28683447 [TBL] [Abstract][Full Text] [Related]
13. Don't forget these 5 things when treating hidradenitis suppurativa. Tracey EH Cutis; 2019 Nov; 104(5):E27-E28. PubMed ID: 31886798 [TBL] [Abstract][Full Text] [Related]
14. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Zouboulis CC; Desai N; Emtestam L; Hunger RE; Ioannides D; Juhász I; Lapins J; Matusiak L; Prens EP; Revuz J; Schneider-Burrus S; Szepietowski JC; van der Zee HH; Jemec GB J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):619-44. PubMed ID: 25640693 [TBL] [Abstract][Full Text] [Related]
15. Psychiatric comorbidities in patients with hidradenitis suppurativa. Misitzis A; Goldust M; Jafferany M; Lotti T Dermatol Ther; 2020 Jul; 33(4):e13541. PubMed ID: 32385861 [TBL] [Abstract][Full Text] [Related]
16. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa. Garcovich S; Genovese G; Moltrasio C; Malvaso D; Marzano AV Clin Dermatol; 2021; 39(2):240-247. PubMed ID: 34272017 [TBL] [Abstract][Full Text] [Related]
17. Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. Giovanardi G; Chiricozzi A; Bianchi L; De Simone C; Dini V; Franceschini C; Garcovich S; Oranges T; Di Raimondo C; Caposiena Caro DR; Romanelli M; Peris K Dermatology; 2018; 234(1-2):66-70. PubMed ID: 29689550 [TBL] [Abstract][Full Text] [Related]
18. Targeting Metabolic Syndrome in Hidradenitis Suppurativa by Phytochemicals as a Potential Complementary Therapeutic Strategy. Witte K; Wolk K; Witte-Händel E; Krause T; Kokolakis G; Sabat R Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686829 [TBL] [Abstract][Full Text] [Related]
19. Recommendations for the management of comorbidity in hidradenitis suppurativa. Dauden E; Lazaro P; Aguilar MD; Blasco AJ; Suarez C; Marin I; Queiro R; Bassas-Vila J; Martorell A; García-Campayo J J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):129-144. PubMed ID: 28796920 [TBL] [Abstract][Full Text] [Related]
20. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa. Fischer AH; Jourabchi N; Khalifian S; Lazarus GS Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]